Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
K. Numata
Observed name:
Kazushi Numata
Institutions:
Yokohama City University Medical Center,
Yokohama City University Hospital
Observed institutions:
Yokohama City University Medical Center,
Yokohama City University Hospital
ORCID:
0000-0003-4671-4431
Observed ORCID:
0000-0003-4671-4431
OpenAlex ID:
A5091811973
Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
2019
·
C.-H. Hsu
, M.S. Lee
, et al.
·
Annals of Oncology
·
26
PDF
Oncogenic function and transcriptional dynamics of MYCN in liver tumorigenesis
2026
·
Xian-Yang Qin
, Yali Xu
, et al.
·
Proceedings of the National Academy of Sciences
·
4
73MO Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Final analysis of the prospective, observational REFINE study
2022
·
Y.J. Kim
, M. Kurosaki
, et al.
·
Annals of Oncology
·
1
126O Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW Asian subgroup analysis
2024
·
T. Yau
, P.R. Galle
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
4
Citation count:
31
H-index:
2
I10-index:
1
Year
Topic
Type